Showing results (111-120 of 202) with videos related to

Sort By:
Pageof 21
Cancer Immunology, Immunotherapy : CII|January 13, 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaValerie Glutsch, Hermann Kneitz, Anja Gesierich, et al.
Cardiovascular Research|November 13, 2014
Erk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1Ravi K Komaravolu, Christian Adam, Jan-Renier A J Moonen, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Comorbidities significantly impact patients' preferences for psoriasis treatmentsAstrid Schmieder, Marthe-Lisa Schaarschmidt, Nasir Umar, et al.
Cell Death & Disease|October 6, 2025
MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progressionRupesh Paudel, Simon Goller, Felix Deutzmann, et al.
Molecular Oncology|October 4, 2019
The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesisChristine Hoesl, Thomas Fröhlich, Jennifer E Hundt, et al.
Cancer Letters|March 23, 2016
Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cellsGuannan Zhu, Xiuli Yi, Sebastian Haferkamp, et al.
Cancers|November 11, 2022
Panel Sequencing of Primary Cutaneous B-Cell LymphomaMarion Wobser, Patrick Schummer, Silke Appenzeller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
The contact allergen nickel triggers a unique inflammatory and proangiogenic gene expression pattern via activation of NF-kappaB and hypoxia-inducible factor-1alphaDorothee Viemann, Marc Schmidt, Klaus Tenbrock, et al.
The Journal of Investigative Dermatology|March 10, 2020
Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative DisordersKatja Maurus, Silke Appenzeller, Sabine Roth, et al.
Pageof 21